Complete remission with imatinib mesylate (Glivec®) of an idiopathic hypereosinophilic syndrome associated with a cutaneous mastocytosis after failure of interferon-alpha;Rémission complète sous imatinib mésylate (Glivec®) d'un syndrome hyperéosinophilique myéloprolifératif associé à une mastocytose cutanée résistant à l'interféron alpha

Revue de Medecine Interne

Volumn 24, Issue 8, 2003, Pages 542-546

  Pottier, P ^a   Planchon, B ^a   Grossi, O ^a  

^a HÔTEL DIEU   (France)

Author keywords

Immunosuppressive agents; Leukemia myeloid; Philadelphia negative; Urticaria pigmentosa

Indexed keywords

ALPHA INTERFERON; CYCLOPHOSPHAMIDE; FLUINDIONE; HYDROXYUREA; IMATINIB; METHYLPREDNISOLONE SODIUM SUCCINATE;

ADULT; ARTICLE; CASE REPORT; CHRONIC MYELOID LEUKEMIA; CLINICAL FEATURE; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG SAFETY; HUMAN; HYPEREOSINOPHILIC SYNDROME; IDIOPATHIC DISEASE; MALE; REMISSION; TREATMENT FAILURE; URTICARIA PIGMENTOSA;

EID: 0043173875     PISSN: 02488663     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0248-8663(03)00192-9     Document Type: Article

References (20)

1. Masi AT, Hunder GG, Lie JT, Michel BA, Bloch DA, Arend WP, et al. The American College of Rheumatology 1990 classification criteria of Churg-Strauss syndrome. Arthritis Rheum 1990;33:1094-100.
2. Mc Elroy EA, Philiky RL, Li CY. Systemic mast cell disease associated with the hypereosinophilic syndrome. Mayo Clin Proc 1998;73:47-50.
3. Hauswirth AW, Speer WE, Ghannadan M, Schernthaner GH, Jordan JH, Fritsche-Polanz R, et al. A case of smoldering mastocytosis with peripheral blood eosinophilia and lymphadenopathy. Leuk Res 2002;26:601-6.
4. Chambers LA, Leonard SS, Wathmough AE, Weller PF, Bubley GJ, Kruskall MS. Management of hypereosinophilic syndrome with chronic plasma and leukapheresis. Prog Clin Biol Res 1990;337:83-5.
5. Smith AJ, van Essen LH, de Vries EG. Sucessful long-term control of idiopathic hypereosinophilic syndrome with etoposide. Cancer 1991;67:2826-7.
6. Sakamoto K, Erdreich-Epstein A, deClerck Y, Coates T. Prolonged clinical response to vincristine treatment in 2 patients with idiopathic hypereosinophilic syndrome. Am J Pediatr Hematol Oncol 1992;14:348-51.
7. Ueno NT, Zhao S, Robertson LE, Consoli U, Andreeff M. Chlorodeoxyadenosine therapy for idiopathic hypereosinophilic syndrome. Leukemia 1997;11:1386-90.
8. Sigmund DA, Flessa HC. Hypereosinophilic syndrome: successful allogenic bone marrow transplantation. Bone Marrow Transplant 1995;15:647-8.
9. Fukushima T, Kuriyama K, Ito H, Miyazaki Y, Arimura K, Hata T, et al. Successful bone marrow transplantation for idiopathic hypereosinophilic syndrome. Br J Haematol 1995;90:213-5.
10. Butterfield JH, Gleich GJ. Interferon-alpha treatment of 6 patients with the idiopathic hypereosinophilic syndrome. Ann Intern Med 1994;121:648-53.
11. Ceretelli S, Capochiani E, Petrini M. Interferon-alpha in the idiopathic hypereosinophilic syndome: consideration of five cases. Ann Hematol 1998;77:161-4.
12. Yamada O, Kitahara K, Imamura K, Ozasa H, Okada M, Mizoguchi H. Clinical and cytogenetic remission induced by interferon-alpha in a patient with chronic eosinophilic leukemia associated with a unique t(3;9;5) translocation. Am J Hematol 1998;58:137-41.
13. Baratta L, Afeltra A, Delfino M, De Castro S, Giorgino F, Ross-Fanelli F. Favorable response to high-dose interferon-alpha in idiopathic hypereosinophilic syndrome with restrictive cardiomyopathy. Report and literature review. Angiology 2002;53:465-70.
14. Kantarjian HM, Tampaz M, O'Brien S, Smith TL, Gilmes FJ, Faderl S, et al. Imatinib mesylate for Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interfeon-alpha: follow-up results. Clin Cancer Res 2002;8:2177-87.
15. Shaller JL, Burkland GA. Case report: rapid and complete control of idiopathic hypereosinophilia with imatinib mesylate. MedGenMed 2001;3:9.
16. Gleich GJ, Leiferman KM, Pardanani A, Teffery A, Butterfield J. Treatment of hypereosinophilic syndrome with imatinib mesylate. Lancet 2002;359:1577-8.
17. Ault P, Cortes J, Koller C, Kaled ES, Kantarjian H. Response of idiopathic hypereosinophilic syndrome to treatment with imatinib mesylate. Leukemia Res 2002;26:881-4.
18. Dupire S, Kuhnowski F, Bourgeois E, Cambier N, Preudhomme C, Capron M, et al. Réponse complète sous imatinib d'un syndrome hyperéosinophilique en rechute après allogreffe. Rev Méd Interne 2002;23(suppl 2):682.
19. Cools J, DeAngelo DJ, Gotlib J, Stover EH, Legare RD, Cortes J, et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosionophilic syndrome. N Engl J Med 2003;348:1199-200.
20. Longley Jr BJ, Morganroth GS, Tyrell L, Ding TG, Anderson DM, Williams DE, et al. Altered metabolism of mast-cell growth factor (c-kit ligand) in cutaneous mastocytosis. N Engl J Med 1993;328:1302-7.